

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

Nemauro Medical Inc.

Form: 8-K

Date Filed: 2018-06-27

Corporate Issuer CIK: 1602078

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934

Date of Report (Date of earliest event reported): **June 27, 2018**

NEMAURA MEDICAL, INC.

(Exact name of registrant as specified in charter)

Nevada

(State or other jurisdiction of incorporation)

001-38355

(Commission File Number)

46-5027260

(IRS Employer Identification No.)

Advanced Technology Innovation Centre,
Loughborough University Science and Enterprise Parks,
5 Oakwood Drive,
Loughborough, Leicestershire LE11 3QF
United Kingdom

(Address of principal executive offices)

N/A

(Zip Code)

Registrant's telephone number, including area code:

00 44 1509 222912

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01. Other Events

Nemauro Medical, Inc. (the "Registrant"), has terminated the public offering of shares of its common stock which was being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on March 31, 2016. The termination results from an assessment by the Company's management that a public offering on the terms provided would not be in the best interests of the Company's shareholders. As a result of such termination, no shares will be sold pursuant to the offering.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Nemauro Medical, Inc.

By: /s/ Dewan F. H. Chowdhury

Name: Dewan F. H. Chowdhury

Title: Chief Executive Officer

Dated: June 27, 2018